Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Earnings for Theseus Pharmaceuticals, Inc. (THRX)
Earnings in 2022 (TTM): $-50,608,000
According to Theseus Pharmaceuticals, Inc.'s latest financial reports the company's current earnings (TTM) are $-50,608,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Theseus Pharmaceuticals, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2022 | $-50,608,000 | $-47,080,000 |
| 2021 | $-27,308,000 | $-27,308,000 |
| 2020 | $-11,997,000 | $-11,997,000 |
| 2019 | $-7,183,000 | $-7,183,000 |